CN114736196B - Violet Luo Zhulian and side chain coupling post-treatment purification process - Google Patents

Violet Luo Zhulian and side chain coupling post-treatment purification process Download PDF

Info

Publication number
CN114736196B
CN114736196B CN202210524300.4A CN202210524300A CN114736196B CN 114736196 B CN114736196 B CN 114736196B CN 202210524300 A CN202210524300 A CN 202210524300A CN 114736196 B CN114736196 B CN 114736196B
Authority
CN
China
Prior art keywords
luo
side chain
zhulian
bromohexyloxy
purification process
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202210524300.4A
Other languages
Chinese (zh)
Other versions
CN114736196A (en
Inventor
张启龙
许坤
王红磊
汪崇文
李登阳
史帅帅
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anhui Dexinjia Biopharm Co ltd
Original Assignee
Anhui Dexinjia Biopharm Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anhui Dexinjia Biopharm Co ltd filed Critical Anhui Dexinjia Biopharm Co ltd
Priority to CN202210524300.4A priority Critical patent/CN114736196B/en
Publication of CN114736196A publication Critical patent/CN114736196A/en
Application granted granted Critical
Publication of CN114736196B publication Critical patent/CN114736196B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/63One oxygen atom
    • C07D213/68One oxygen atom attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79Acids; Esters
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79Acids; Esters
    • C07D213/803Processes of preparation
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

The invention discloses a purification process for coupling of Violet Luo Zhulian and a side chain, and belongs to the field of drug synthesis. Willand Luo Zhulian 2- [2- (6-Bromohexyloxy) ethoxymethyl ] -1, 3-dichlorobenzene is coupled with the side chain (5R) -5- (2, 2-dimethyl-4H-1, 3-benzodioxan-6-yl) -1, 3-oxazolidin-2-one, excess backbone 2- [2- (6-Bromohexyloxy) ethoxymethyl ] -1, 3-dichlorobenzene is reacted with pyridine derivative to form a salt, and the salt is washed with hot water at 50 ℃. The method has the advantages of mild reaction conditions of salifying by using the pyridine derivative which is low in cost and easy to obtain, simple operation and easy removal of impurities, avoids purification products by a silica gel chromatographic column purification and distillation method, and is suitable for industrial production.

Description

Violet Luo Zhulian and side chain coupling post-treatment purification process
Technical Field
The invention belongs to the field of synthesis of pharmaceutical intermediates, and relates to a purification process for coupling of Violet Luo Zhulian and side chains.
Background
Veland Luo San phenylacetate (Vilanterol trifenatate) is a long acting β2 receptor agonist developed by the company Glazin Smik (GSK). The compound preparation of the medicine and the fluticasone furoate and the compound preparation of the medicine and the turnip bromide are approved by the FDA in 5 months and 12 months in 2013 respectively, and are used for treating obstructive pulmonary disease and asthma. Wherein, (5R) -3- [6- [2- [ (2, 6-dichlorophenyl) methoxy]Ethoxy group]Hexyl group]-5- (2, 2-dimethyl-4H-1, 3-benzodioxin-6-yl) -2-oxazolidinone is a key intermediate for the synthesis of vilantro, CAS:503068-36-8, molecular formula: c (C) 28 H 35 Cl 2 NO 6 Molecular weight: 552.49, which is subjected to two steps of reaction to obtain the vilantro, the specific reaction is as follows:
Figure BDA0003643452360000011
currently, the synthesis of (5R) -3- [6- [2- [ (2, 6-dichlorophenyl) methoxy ] ethoxy ] hexyl ] -5- (2, 2-dimethyl-4H-1, 3-benzodioxin-6-yl) -2-oxazolidinone is mainly carried out using the following procedure (reference: US 2015239862A):
Figure BDA0003643452360000012
the route adopts the coupled reaction of vilantt Luo Zhulian 2- [2- (6-bromohexyloxy) ethoxymethyl ] -1, 3-dichlorobenzene and a side chain (5R) -5- (2, 2-dimethyl-4H-1, 3-benzodioxan-6-yl) -1, 3-oxazolidin-2-ketone to obtain (5R) -3- [6- [2- [ (2, 6-dichlorophenyl) methoxy ] ethoxy ] hexyl ] -5- (2, 2-dimethyl-4H-1, 3-benzodioxin-6-yl) -2-oxazolidinone under the effect of potassium tert-butoxide. Because the vilanabro side chain intermediate (5R) -5- (2, 2-dimethyl-4H-1, 3-benzodioxan-6-yl) -1, 3-oxazolidin-2-one is chiral and requires at least 7 steps of reaction synthesis, it is relatively expensive and an excess of the vilanabro main chain intermediate is typically added in the process to ensure complete conversion of the side chain intermediate. However, the synthesized product (5R) -3- [6- [2- [ (2, 6-dichlorophenyl) methoxy ] ethoxy ] hexyl ] -5- (2, 2-dimethyl-4H-1, 3-benzodioxin-6-yl) -2-oxazolidone and the main chain raw material are all relatively viscous liquid at normal temperature, and purification by recrystallization is difficult, and meanwhile, the two compounds have relatively high boiling points, the boiling point is about 420.8+/-45.0 ℃ (760 Torr), and the product is easy to decompose at high temperature, so that purification by distillation is difficult. At present, the industry mainly depends on silica gel chromatographic column purification, the production efficiency is limited, and industrialization is difficult to realize.
Disclosure of Invention
Aiming at the defects in the prior art, the invention provides a process for coupling, post-treatment and purification of a vilantrum Luo Zhulian and a side chain, wherein the vilantrum Luo Zhulian- [2- (6-bromohexyloxy) ethoxymethyl ] -1, 3-dichlorobenzene and the side chain (5R) -5- (2, 2-dimethyl-4H-1, 3-benzodioxan-6-yl) -1, 3-oxazolidine-2-ketone are subjected to a coupling reaction, and excessive main chain 2- [2- (6-bromohexyloxy) ethoxymethyl ] -1, 3-dichlorobenzene reacts with pyridine derivatives to form salts, and then the salts are washed by hot water to remove impurities, wherein the specific salification reaction is as follows:
Figure BDA0003643452360000021
the pyridine derivative is one of pyridine, 2-picolinic acid, 2-hydroxypyridine, 2-aminopyridine, 3-picolinic acid, 3-hydroxypyridine, 3-aminopyridine, 4-picolinic acid, 4-hydroxypyridine and 4-aminopyridine, and preferably 2-picolinic acid, 3-picolinic acid and 4-picolinic acid; after the coupling reaction of the main chain and the side chain is finished, the added pyridine derivative is 10% of the molar quantity of 2- [2- (6-bromohexyloxy) ethoxymethyl ] -1, 3-dichlorobenzene; the pyridine derivative is directly added into a reaction system after the coupling reaction of the main chain and the side chain is finished; the reaction solvent is DMF; the temperature of the hot water is 50 ℃; the reaction time after the pyridine derivative is added is 2 hours.
The invention has the beneficial effects that:
(1) The invention adopts pyridine derivative to wash away excessive main chain 2- [2- (6-bromohexyloxy) ethoxymethyl ] -1, 3-dichlorobenzene after salifying, and the purity of the product can reach more than 99% without purification by silica gel chromatographic column or distillation.
(2) The method is simple to operate, thorough in removal and feasible in large-scale industrial production.
Detailed Description
Example 1:
to a 100L reactor was added (5R) -5- (2, 2-dimethyl-4H-1, 3-benzodioxan-6-yl) -1, 3-oxazolidin-2-one (2.5 kg,10.0 mol) with DMF (20 kg). Potassium tert-butoxide (1.2 kg,10.5 mol) was added to the reaction system in portions at a temperature of less than 30℃for 1 hour, and the mixture was stirred for 1 hour after the addition. 2- [2- (6-Bromohexyloxy) ethoxymethyl was added dropwise at 30-35℃over 1.5 hours]-1, 3-dichlorobenzene (4.2 kg,11.0mol, diluted with 5kg of DMF), stirring at 30-35 ℃ for 2 hours, liquid phase control until complete consumption of (5R) -5- (2, 2-dimethyl-4H-1, 3-benzodioxan-6-yl) -1, 3-oxazolidin-2-one. After that, the process is carried out,4-Pyridinecarboxylic acid (0.135 kg) was added to the reaction system, and stirring was continued at 50℃for 2 hours. Ethyl acetate (25 kg) and water (25 kg) were added to the reaction system, and the mixture was stirred at 50℃for 1 hour. The layers were separated and the organic phase was washed twice with saturated NaCl (10kg+10kg) solution and twice with water (10kg+10kg). The organic phase is added with Na 2 SO 4 (2 kg) drying, filtering, and distilling the filtrate under reduced pressure to remove the solvent to obtain (5R) -3- [6- [2- [ (2, 6-dichlorophenyl) methoxy]Ethoxy group]Hexyl group]-5- (2, 2-dimethyl-4H-1, 3-benzodioxin-6-yl) -2-oxazolidinone as pale yellow oil (5.1 kg, 92% yield, 99.1% purity in liquid phase, 2- [2- (6-bromohexyloxy) ethoxymethyl group)]-1, 3-dichlorobenzene content < 0.1%).
Example 2:
to a 100L reactor was added (5R) -5- (2, 2-dimethyl-4H-1, 3-benzodioxan-6-yl) -1, 3-oxazolidin-2-one (2.5 kg,10.0 mol) with DMF (20 kg). Potassium tert-butoxide (1.2 kg,10.5 mol) was added to the reaction system in portions at a temperature of less than 30℃for 1 hour, and the mixture was stirred for 1 hour after the addition. 2- [2- (6-Bromohexyloxy) ethoxymethyl was added dropwise at 30-35℃over 1.5 hours]-1, 3-dichlorobenzene (4.2 kg,11.0mol, diluted with 5kg of DMF), stirring at 30-35 ℃ for 2 hours, liquid phase control until complete consumption of (5R) -5- (2, 2-dimethyl-4H-1, 3-benzodioxan-6-yl) -1, 3-oxazolidin-2-one. Thereafter, 4-picolinic acid (0.135 kg) was added to the reaction system and stirring was continued for 1 hour at 50℃by heating. Ethyl acetate (25 kg) and water (25 kg) were added to the reaction system, and the mixture was stirred at 50℃for 1 hour. The layers were separated and the organic phase was washed twice with saturated NaCl (10kg+10kg) solution and twice with water (10kg+10kg). The organic phase is added with Na 2 SO 4 (2 kg) drying, filtering, and distilling the filtrate under reduced pressure to remove the solvent to obtain (5R) -3- [6- [2- [ (2, 6-dichlorophenyl) methoxy]Ethoxy group]Hexyl group]-5- (2, 2-dimethyl-4H-1, 3-benzodioxin-6-yl) -2-oxazolidinone as a pale yellow oil (5.1 kg, 92% yield, 98.8% purity in liquid phase, 2- [2- (6-bromohexyloxy) ethoxymethyl group)]-1, 3-dichlorobenzene content 0.6%).
Example 3:
(5R) -5- (2, 2-dimethyl-4H-1, 3-Benzodioxan-6-yl) -1, 3-oxazolidin-2-one (250) was added to a 10L reactorg,1.0 mol), DMF (2 kg). Potassium tert-butoxide (120 g,1.05 mol) was added to the reaction system in portions at a temperature of less than 30℃for 1 hour, and the mixture was stirred for 1 hour after the addition. 2- [2- (6-Bromohexyloxy) ethoxymethyl was added dropwise at 30-35℃over 1.5 hours]-1, 3-dichlorobenzene (420 g,1.1mol, diluted with 500g of DMF), stirred at 30-35℃for 2 hours, liquid phase control until complete consumption of (5R) -5- (2, 2-dimethyl-4H-1, 3-benzodioxan-6-yl) -1, 3-oxazolidin-2-one. Thereafter, 4-hydroxypyridine (104 g) was added to the reaction system, and stirring was continued for 2 hours at 50℃with heating. Ethyl acetate (25 kg) and water (25 kg) were added to the reaction system, and the mixture was stirred at 25℃for 1 hour. Ethyl acetate (2.5 kg) and water (2.5 kg) were added to the reaction system, and the mixture was stirred at 25℃for 1 hour. The layers were separated and the organic phase was washed twice with saturated NaCl (1 kg+1 kg) solution and twice with water (1 kg+1 kg). The organic phase is added with Na 2 SO 4 (200g) Drying, filtering, and distilling the filtrate under reduced pressure to remove the solvent to obtain (5R) -3- [6- [2- [ (2, 6-dichlorophenyl) methoxy]Ethoxy group]Hexyl group]-5- (2, 2-dimethyl-4H-1, 3-benzodioxin-6-yl) -2-oxazolidinone as pale yellow oil (497 g, 91% yield, 98.3% purity in liquid phase, 2- [2- (6-bromohexyloxy) ethoxymethyl)]-1, 3-dichlorobenzene content 0.8%).
Example 4:
to a 10L reactor was added (5R) -5- (2, 2-dimethyl-4H-1, 3-benzodioxan-6-yl) -1, 3-oxazolidin-2-one (250 g,1.0 mol) and DMF (2 kg). Potassium tert-butoxide (120 g,1.05 mol) was added to the reaction system in portions at a temperature of less than 30℃for 1 hour, and the mixture was stirred for 1 hour after the addition. 2- [2- (6-Bromohexyloxy) ethoxymethyl was added dropwise at 30-35℃over 1.5 hours]-1, 3-dichlorobenzene (420 g,1.1mol, diluted with 500g of DMF), stirred at 30-35℃for 2 hours, liquid phase control until complete consumption of (5R) -5- (2, 2-dimethyl-4H-1, 3-benzodioxan-6-yl) -1, 3-oxazolidin-2-one. Ethyl acetate (2.5 kg) and water (2.5 kg) were added to the reaction system, and the mixture was stirred at 50℃for 1 hour. The layers were separated and the organic phase was washed twice with saturated NaCl (1 kg+1 kg) solution and twice with water (1 kg+1 kg). The organic phase is added with Na 2 SO 4 (200g) Drying, filtering, and distilling the filtrate under reduced pressure to remove the solvent to obtain (5R) -3- [6- [2- [ (2, 6-dichlorophenyl) base) Methoxy group]Ethoxy group]Hexyl group]-5- (2, 2-dimethyl-4H-1, 3-benzodioxin-6-yl) -2-oxazolidinone as pale yellow oil (514 g, 93% yield, 92.6% purity in liquid phase, 2- [2- (6-bromohexyloxy) ethoxymethyl)]-1, 3-dichlorobenzene content 7.3%).
While the foregoing describes the embodiments of the present invention, it should be understood that the present invention is not limited to the embodiments, and that various modifications and changes can be made by those skilled in the art without any inventive effort.

Claims (6)

1. After the coupling reaction of the Violet Luo Zhulian and the side chain, the Violet Luo Zhulian- [2- (6-bromohexyloxy) ethoxymethyl ] -1, 3-dichlorobenzene and the side chain (5R) -5- (2, 2-dimethyl-4H-1, 3-benzodioxan-6-yl) -1, 3-oxazolidine-2-ketone are subjected to the coupling reaction, pyridine derivatives are added to react with excessive 2- [2- (6-bromohexyloxy) ethoxymethyl ] -1, 3-dichlorobenzene to form salts, and the salts are removed by heating, wherein the specific salt forming reaction is as follows:
Figure FDA0004130385050000011
wherein r=4-COOH; 4-OH.
2. A purification process according to claim 1, wherein the pyridine derivative is added in an amount of 10% of the molar amount of 2- [2- (6-bromohexyloxy) ethoxymethyl ] -1, 3-dichlorobenzene.
3. The purification process of claim 1, wherein the heating temperature is 50 ℃.
4. The purification process of claim 1, wherein the pyridine derivative is directly added to the reaction system.
5. A purification process according to claim 1, wherein the reaction solvent is DMF.
6. A purification process according to claim 1, wherein the reaction time after adding pyridine derivatives is 2h.
CN202210524300.4A 2022-05-13 2022-05-13 Violet Luo Zhulian and side chain coupling post-treatment purification process Active CN114736196B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210524300.4A CN114736196B (en) 2022-05-13 2022-05-13 Violet Luo Zhulian and side chain coupling post-treatment purification process

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202210524300.4A CN114736196B (en) 2022-05-13 2022-05-13 Violet Luo Zhulian and side chain coupling post-treatment purification process

Publications (2)

Publication Number Publication Date
CN114736196A CN114736196A (en) 2022-07-12
CN114736196B true CN114736196B (en) 2023-06-13

Family

ID=82284856

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202210524300.4A Active CN114736196B (en) 2022-05-13 2022-05-13 Violet Luo Zhulian and side chain coupling post-treatment purification process

Country Status (1)

Country Link
CN (1) CN114736196B (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111377822B (en) * 2018-12-29 2023-09-08 天津药业研究院股份有限公司 Preparation method of vilanaflo
CN109574860B (en) * 2019-01-22 2021-07-27 安徽德信佳生物医药有限公司 Method for preparing vilanterol
EP4013398A4 (en) * 2019-08-16 2023-12-27 Melody Healthcare Pvt. Ltd. An improved process for preparation of vilanterol or a pharmaceutically acceptable salt thereof

Also Published As

Publication number Publication date
CN114736196A (en) 2022-07-12

Similar Documents

Publication Publication Date Title
JPS6327462A (en) Manufacture of o-substituted hydroxylamine
CN116640088A (en) Preparation method of high-purity Lei Fen narasin
CN114736196B (en) Violet Luo Zhulian and side chain coupling post-treatment purification process
CN106588718A (en) Preparation method of 2-(methyl sulphonyl)-1-aromatic ethylamine
CN108623455B (en) Intermediate of anti-heart failure medicine
JPS6330448A (en) Manufacture of chlorocarboxylic acid chloride
CN111574444A (en) Preparation method of bedaquiline
CN108947800B (en) Synthesis method of (1S) -4, 5-dimethoxy-1- (carbonylaminomethyl) benzocyclobutane
CN114181074B (en) Preparation method of p-chlorobenzoyl fluoride
CN114213424B (en) Synthesis method of furan [3,2-b ] pyridine derivative
CN111269149B (en) Production process of 5- (3,3-dimethylguanidino) -2-oxopentanoic acid
CN110256451B (en) Synthetic method of benzofuro [2,3-b ] quinoline derivative
CN110003101B (en) Apatinib intermediate and preparation method thereof
CN109678701B (en) Preparation method of vilanterol intermediate
CN111303047A (en) Synthesis method of 2-amino-4, 6-dimethylpyridine
CN105037193A (en) Preparation method of otilonium bromide
CN110845405A (en) Synthesis method of 7-chloroquinaldine
JP6410989B2 (en) Method for preparing thiophene-2-carbonyl chlorides using oxalyl chloride
CN111072475A (en) Synthesis method and application of 1-hydroxymethyl cyclopropyl acetic acid
CN113735693B (en) Synthesis method of resveratrol dimethyl ether
CN108715576A (en) A kind of preparation method of 3- ethyoxyl-4-carboxylphenylaceticacid acids
CN112174877B (en) Preparation method of 2, 4-diaryl-6-trifluoromethylpyridine derivative
CN113402452B (en) Method for preparing 2-chloro-5-substituted pyridine
CN111635368B (en) Preparation method of amine compound
JPS639495B2 (en)

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant